## Edgar Filing: NEWLINK GENETICS CORP - Form 4

Form 4	GENETICS COI	RP										
<b>FORN</b> Check th if no lon subject t Section Form 4 o Form 5 obligation may com	obligations may continue. See Instruction See							OMB APPROVAL OMB 3235-0287 Number: January 31, Expires: 2005 Estimated average burden hours per response 0.5				
(Print or Type	Responses)											
1. Name and Address of Reporting Person <u>*</u> Vahanian Nicholas N.			2. Issuer Name and Ticker or Trading Symbol NEWLINK GENETICS CORP [(NLNK)]					-	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)			
(Last) (First) (Middle) C/O NEWLINK GENETICS CORPORATION, 2503 SOUTH LOOP DR., SUITE 5100			3. Date of Earliest Transaction (Month/Day/Year) 02/03/2014						Director 10% Owner X Officer (give title Other (specify below) President, Chief Medical Offic			
	(Street)			endment, I nth/Day/Ye		e Original			6. Individual or Joi Applicable Line) _X_ Form filed by O Form filed by M	ne Reporting Per	rson	
AMES, IA (City)	(State)	(Zip)							Person			
1.Title of Security (Instr. 3)	(State) 2. Transaction Dat (Month/Day/Year)	e 2A. Deer Executio any		3.	tion )	erivative 5 4. Securiti (A) or Dis (Instr. 3, 4 Amount	ies Ac sposed	quired of (D)	irred, Disposed of, 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	or Beneficial 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect	
Common Stock	02/03/2014			S <u>(1)</u>		20,000	D	\$ 35.87 (2)	44,144 <u>(3)</u>	D		
Common Stock	02/04/2014			S <u>(1)</u>		10,000	D	\$ 36.78 (4)	34,144 <u>(3)</u>	D		
Common Stock	02/04/2014			М		15,000	А	\$ 2.1	49,144 <u>(3)</u>	D		
Common	02/04/2014			<b>S</b> <sup>(1)</sup>		15.000	D	\$	34,144 (3)	D		

## Edgar Filing: NEWLINK GENETICS CORP - Form 4

Stock		-	-		36.78 (4)					
Common Stock						52,856	II	By Spouse		
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.										
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned         (e.g., puts, calls, warrants, options, convertible securities)										
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	5. Number of orDerivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisab Expiration Date (Month/Day/Year		7. Title and A Underlying S (Instr. 3 and	Securities	
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Share	
Stock Option (Right to Buy)	\$ 2.1	02/04/2014		М	15,000	06/01/2008 <u>(5)</u>	05/12/2019	Common Stock	15,000	

## **Reporting Owners**

<b>Reporting Owner Name / Address</b>	Relationships							
	Director	10% Owner	Officer	Other				
Vahanian Nicholas N. C/O NEWLINK GENETICS CORPORAT 2503 SOUTH LOOP DR., SUITE 5100 AMES, IA 50010	ION		President, Chief Medical Offic					
Signatures								
/s/ Gordon Link, by power of attorney	02/05/2014							
<u>**</u> Signature of Reporting Person	Date							
<b>Explanation of Respons</b>	es:							

\* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

## Edgar Filing: NEWLINK GENETICS CORP - Form 4

- (1) The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on 10/28/2013.
- (2) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$35.77
   (2) to \$35.99, inclusive. The reporting person undertakes to provide to the issuer, any security holder of issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the ranges set forth in this footnote to this Form 4.

(3) Includes 15,000 restricted stock units ("RSUs") previously reported as holdings of the Reporting Person granted under the Issuer's 2009 Equity Incentive Plan (the "Plan"). The RSUs will vest, and shares will be delivered to the Reporting Person in a series of four successive annual installments beginning on January 2, 2015, provided in each case that the Reporting Person's continuous service to the Issuer has not been terminated as defined in or as determined under the Plan.

(4) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$36.02 to \$37.38, inclusive. The reporting person undertakes to provide to the issuer, any security holder of issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the ranges set forth in this footnote to this Form 4.

Grant to the Reporting Person of a stock option under the Plan. The option vests over a five-year period, with 20% of such option vesting on the one-year anniversary of the vesting commencement date and the remaining 80% of such option vesting in equal monthly

(5) on the one-year anniversary of the vesting commencement date and the remaining 80% of such option vesting in equal monthly installments over the next 48 months, provided that at the relevant vesting dates the Reporting Person's continuous service to the Issuer has not been terminated as defined in or as determined under the Plan. The option expires ten years after the date of grant.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.